ELEKTA TO DELIVER FIRST LEKSELL GAMMA KNIFE® UNIT TO RUSSIA

ELEKTA TO DELIVER FIRST LEKSELL GAMMA KNIFE® UNIT TO RUSSIA Burdenko Neurosurgical Institute in Moscow will add non-invasive brain surgery to its range of advanced treatment methods Recently, Elekta finalized the contract with Finance Leasing Company (Moscow, Russia) and Neurosurgical Business Center (NBC) for Burdenko Neurosurgical Institute to deliver Leksell Gamma Knife®, the gold standard equipment for non-invasive Gamma Knife® surgery. This Leksell Gamma Knife® unit is the first to be installed in Russia, serving a previously unmet need for non-invasive treatment of small to medium size intracranial lesions. "We are very excited about the prospect of adding Leksell Gamma Knife® to our advanced treatment methods here at Burdenko", says Dr. Nikolay Alexandrovich Konovalov, Director of the Institute. "Continuing our tradition of being at the forefront of microsurgery and minimally invasive treatments, the addition of Gamma Knife® surgery will provide us with a method to treat a variety of brain tumors, vascular malformations and functional diseases that will be of great benefit to our patients. The non-invasive technique of Gamma Knife® surgery offers important benefits. We are in high demand for these treatments and I expect a high patient volume on our Leksell Gamma Knife® unit", Dr Konovalov concludes. "Gamma Knife® surgery revolutionized the treatment of brain disorders when it was introduced over thirty years ago. Today, the potential for its use and the benefits that it brings are bigger than ever. It is with great pride that we now are going to supply the first Leksell Gamma Knife® unit to Russia", says Thomas Meyer von der Twer, Director of European sales of neurosurgery products at Elekta, and continues: "It is also an honor to welcome the esteemed Dr Konovalov and his colleagues to Leksell Gamma Knife Society and to the sharing of experiences, new results and solutions to clinical problems that to this day has produced more than 2,000 scientific papers, documenting the results of various treatments with Leksell Gamma Knife®". To date, well over 250,000 patients around the world have been treated with Leksell Gamma Knife®, and each year more than 30,000 new patients are treated at the close to 200 units installed around the world. The total payment for the Leksell Gamma Knife® unit to Burdenko Neurosurgical Institute will amount to 3,8 MEUR. The order was booked by Elekta in February. For further information, please contact: International: Peter Ejemyr, Group VP Corporate Communications, Elekta AB (publ), Phone: +46 733 611 000, e-mail: peter.ejemyr@elekta.com United States: Lars Jonsteg, VP Investor Relations North America, Elekta, USA Phone: +1 770-670-2419, e-mail: lars.jonsteg@elekta.com Elekta is a world-leading supplier of advanced and innovative radiation oncology and neurosurgery solutions and services for precise treatment of cancer and brain disorders. Elekta's solutions are clinically effective, cost efficient and gentle to the patient. For additional information about Elekta, please visit www.elekta.com ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2004/03/25/20040325BIT00530/wkr0001.doc http://www.waymaker.net/bitonline/2004/03/25/20040325BIT00530/wkr0002.pdf

About Us

For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.

Subscribe